Simulations Plus

We offer biosimulation software and solutions which bridge AI/machine learning, PBPK/pharmacokinetics, quantitative systems pharmacology, pharmacometrics
Simulations Plus is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions.
Simulations Plus (SLP)

Simulations Plus develops modeling and simulation software for the pharmaceutical and biotechnology industries. Its software helps pharmaceutical scientists predict key endpoints and dynamics in silico, supporting drug discovery and development decisions. The upcoming earnings release comes during a major corporate transition.
EnergyPlus™ is a building energy simulation program for modeling energy consumption and water use in buildings by engineers, architects, and researchers.
Simulations Plus Releases GastroPlus X,
Simulations Plus announced the release of the completely redesigned GastroPlusX (GPX), the next generation PBPK/PBBM modeling & simulation software.
Simulations Plus , Inc. announced the launch of a technical collaboration with NVIDIA focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intensive modeling applications within the drug development lifecycle.

Simulations Plus and NVIDIA Collaborate to Scale GPU
RESEARCH TRIANGLE PARK, N.C., May 6, 2026 — Simulations Plus , Inc., a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the launch of a technical collaboration with NVIDIA focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intensive modeling applications within the drug development ...
Professional building energy modeling software powered by EnergyPlus. Import CAD plans, run thermal simulations , analyze HVAC systems, and generate NCC/code compliance reports. Free 14-day trial for architects & engineers.

Simulations Plus, NVIDIA Team to Scale GPU
Simulations Plus , Inc., a company vested in AI-accelerated drug development, reports the launch of a technical collaboration with NVIDIA focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intensive modeling applications within the drug development lifecycle ...



RESEARCH TRIANGLE PARK, N.C., June 16, 2026-- Simulations Plus , Inc. (Nasdaq: SLP) (" Simulations Plus " or the "Company"), a global leader in model-informed and AI-accelerated drug development that ...